MYOS RENS Technology Inc. (MYOS), formerly MYOS Corporation, is an early-stage bionutrition and biotherapeutics company. The Company is focused on the discovery, development and commercialization of products that improve muscle health and function essential for the management of sarcopenia, cachexia and degenerative muscle diseases, and as an adjunct to the treatment of obesity. The Company is focused on the discovery, development, and commercialization of nutritional supplements, functional foods, therapeutic products, and other technologies for maintaining the health and performance of muscle tissue. MYOS is evaluating the modulation of myostatin. Its research is focused on developing strategies and therapeutic interventions to address muscle related conditions, including sarcopenia, cachexia, and inherited and acquired muscle diseases. The Company, through its subsidiary, holds the intellectual property pertaining to Fortetropin, which is a dietary supplement.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Special Foods & Welbeing Products
- Sub-Industry: N/A
- Symbol: NASDAQ:MYOS
- CUSIP: N/A
- Web: www.myoscorp.com
Capitalization:- Market Cap: $8.18 million
- Outstanding Shares: 5,844,000
Average Prices:- 50 Day Moving Avg: $1.45
- 200 Day Moving Avg: $2.08
- 52 Week Range: $1.02 - $6.98
P/E:- Trailing P/E Ratio: N/A
- P/E Growth: 0.00
Sales & Book Value:- Annual Revenue: $275,000.00
- Price / Sales: 29.75
- Book Value: $0.87 per share
- Price / Book: 1.61
Profitability:- EBIDTA: ($3,560,000.00)
- Net Margins: -1,441.73%
- Return on Equity: -70.08%
- Return on Assets: -62.23%
Debt:- Current Ratio: 10.06%
- Quick Ratio: 4.45%
Misc:- Average Volume: 112,228 shs.
- Beta: 1.4
- Short Ratio: 6.8
Frequently Asked Questions for MYOS RENS Technology (NASDAQ:MYOS)
What is MYOS RENS Technology's stock symbol?
MYOS RENS Technology trades on the NASDAQ under the ticker symbol "MYOS."
How were MYOS RENS Technology's earnings last quarter?
MYOS RENS Technology Inc. (NASDAQ:MYOS) issued its quarterly earnings data on Monday, November, 14th. The company reported ($0.17) EPS for the quarter. The business earned $0.04 million during the quarter. MYOS RENS Technology had a negative return on equity of 70.08% and a negative net margin of 1,441.73%. View MYOS RENS Technology's Earnings History.
When will MYOS RENS Technology make its next earnings announcement?
Who are some of MYOS RENS Technology's key competitors?
Some companies that are related to MYOS RENS Technology include Immune Pharmaceuticals (IMNP), Transgenomic (PRPO), Anthera Pharmaceuticals (ANTH), OpGen (OPGN), Novogen Limited (NVGN), Dextera Surgical (DXTR), Galena Biopharma (GALE), Cytori Therapeutics (CYTX), CRITICAL OUTCOME T COM NPV(POST REV SPLIT) (COTQF), Celsion Corporation (CLSN), Lombard Medical (EVAR), RXi Pharmaceuticals Corporation (RXII), DelMar Pharmaceuticals (DMPI), Dynatronics Corporation (DYNT), Mateon Therapeutics (MATN), Repros Therapeutics (RPRX), Argos Therapeutics (ARGS) and Acura Pharmaceuticals (ACUR).
Who are MYOS RENS Technology's key executives?
MYOS RENS Technology's management team includes the folowing people:
- Robert J. Hariri M.D., Ph.D., Independent Chairman of the Board
- Joseph Mannello, Chief Executive Officer
- Victor E. Mandel, Director
- Christopher R. Pechock, Director
- Bin Zhou, Director
- Louis J. Aronne, Independent Director
- Ren Ren, Independent Director Global Chairman
Who owns MYOS RENS Technology stock?
MYOS RENS Technology's stock is owned by a number of of institutional and retail investors. Top institutional investors include FMR LLC (1.37%). Company insiders that own MYOS RENS Technology stock include Joseph Mannello, Robert J Hariri and Zhengguang Lyu. View Institutional Ownership Trends for MYOS RENS Technology.
How do I buy MYOS RENS Technology stock?
Shares of MYOS RENS Technology can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is MYOS RENS Technology's stock price today?
One share of MYOS RENS Technology stock can currently be purchased for approximately $1.40.
MarketBeat Community Rating for MYOS RENS Technology (NASDAQ MYOS)MarketBeat's community ratings are surveys of what our community members think about MYOS RENS Technology and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for MYOS RENS Technology (NASDAQ:MYOS) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | No ratings tracked in the last 12 months. |
| Consensus Rating: | N/A (Score: NaN) |
| Consensus Price Target: | N/A |
Analysts' Ratings History for MYOS RENS Technology (NASDAQ:MYOS)
Show:
No equities research coverage for this company has been tracked by MarketBeat.com
Earnings History for MYOS RENS Technology (NASDAQ:MYOS)Earnings History by Quarter for MYOS RENS Technology (NASDAQ MYOS)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 11/13/2017 | | | | | | | | |
| 11/14/2016 | Q3 2016 | | ($0.17) | | $0.04 million | View | N/A |  |
| 11/14/2014 | Q3 2014 | ($0.24) | ($0.73) | $1.90 million | $0.11 million | View | N/A | |
| 8/14/2014 | Q214 | ($0.20) | ($0.32) | $1.70 million | $1.68 million | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for MYOS RENS Technology (NASDAQ:MYOS)No earnings estimates for this company have been tracked by MarketBeat.com
Dividend History for MYOS RENS Technology (NASDAQ:MYOS)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for MYOS RENS Technology (NASDAQ:MYOS)Insider Ownership Percentage: 58.30%
Institutional Ownership Percentage: 2.42%
Insider Trades by Quarter for MYOS RENS Technology (NASDAQ:MYOS)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 9/23/2016 | Zhengguang Lyu | Director | Buy | 50,000 | $1.70 | $85,000.00 | |
| 9/6/2016 | Zhengguang Lyu | Director | Buy | 23,505 | $1.60 | $37,608.00 | |
| 6/17/2016 | Zhengguang Lyu | Director | Buy | 10,000 | $1.65 | $16,500.00 | |
| 4/8/2016 | Joseph Mannello | Director | Buy | 4,417 | $1.96 | $8,657.32 | |
| 4/5/2016 | Joseph Mannello | Director | Buy | 6,128 | $1.75 | $10,724.00 | |
| 9/29/2015 | Robert J. Hariri | Director | Buy | 2,300 | $2.68 | $6,164.00 | |
| 9/25/2015 | Robert J. Hariri | Director | Buy | 12,150 | $2.44 | $29,646.00 | |
| 9/11/2015 | Robert J. Hariri | Director | Buy | 4,000 | $1.73 | $6,920.00 | |
| 9/8/2015 | Robert J. Hariri | Director | Buy | 25,250 | $1.71 | $43,177.50 | |
| 9/4/2015 | Louis J Aronne | Director | Buy | 5,000 | $1.76 | $8,800.00 | |
| 8/28/2015 | Robert J Hariri | Director | Buy | 2,750 | $1.74 | $4,785.00 | |
| 12/4/2014 | Robert J Hariri | Director | Buy | 2,200 | $8.16 | $17,952.00 | |
| 8/18/2014 | Peter Diamandis | Director | Buy | 3,444 | $14.51 | $49,972.44 | |
(Data available from 1/1/2013 forward)
Headline Trends for MYOS RENS Technology (NASDAQ:MYOS)
Latest Headlines for MYOS RENS Technology (NASDAQ:MYOS)
| Source: |
|
| Date | Headline |
|---|
 | BRIEF-Myos Rens Technology Inc appoints Joseph Mannello as permanent CEO
www.reuters.com - September 22 at 10:00 AM |
 | MYOS RENS Technology Inc. Appoints Joseph Mannello as Permanent Chief Executive Officer
finance.yahoo.com - September 22 at 10:00 AM |
| MYOS RENS Technology, Inc. :MYOS-US: Earnings Analysis: Q2, 2017 By the Numbers : August 24, 2017
finance.yahoo.com - August 25 at 8:58 AM |
 | ValuEngine Lowers MYOS RENS Technology Inc. (MYOS) to Strong Sell
www.americanbankingnews.com - August 12 at 7:34 PM |
| MYOS RENS to Introduce the Qurr® Line of Muscle Health Products at 35th IDEA World Convention July 19-23, 2017 in Las Vegas
finance.yahoo.com - July 13 at 7:06 AM |
| ValuEngine Upgrades MYOS RENS Technology Inc. (MYOS) to Sell
www.americanbankingnews.com - July 8 at 10:52 PM |
| MYOS RENS Technology, Inc. :MYOS-US: Earnings Analysis: Q1, 2017 By the Numbers : June 2, 2017
finance.yahoo.com - June 2 at 8:07 PM |
 | How These Generic Drugs Stocks are Faring? -- MYOS RENS Technology, Akari Therapeutics, Flexion Therapeutics, and Zynerba Pharma
www.prnewswire.com - May 19 at 7:13 PM |
| MYOS RENS Will Be Silver Sponsor at International Conference on Frailty and Sarcopenia Research (ICFSR)
finance.yahoo.com - April 24 at 3:35 PM |
| MYOS RENS enters into agreement with Kansas State University to study impact of Fortetropin® on reducing muscle loss in dogs after joint surgery
finance.yahoo.com - April 18 at 10:14 AM |
| MYOS RENS Technology, Inc. :MYOS-US: Earnings Analysis: Q4, 2016 By the Numbers : April 6, 2017
finance.yahoo.com - April 7 at 11:24 AM |
 | MYOS RENS Technology to host April 4 interactive conference call on "Qurr" product launch
us.rd.yahoo.com - March 31 at 9:26 AM |
| Are you Qurr-ious? MYOS Rens Technology Inc. Launches Qurr Product Line Powered by Fortetropin®, an All-Natural Ingredient Clinically Proven to Increase Muscle Size and Mass
finance.yahoo.com - March 13 at 10:13 AM |
| 'Qurr' line of revolutionary muscle-health and muscle-building products in newly-enhanced form set for March rollout
finance.yahoo.com - March 1 at 6:51 PM |
| MYOS RENS TECHNOLOGY INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and Ex
biz.yahoo.com - February 21 at 6:13 PM |
| MYOS RENS TECHNOLOGY INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Material Modification to Ri
us.rd.yahoo.com - February 15 at 2:17 AM |
| MYOS RENS TECHNOLOGY INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Regulation FD Disclosure, F
biz.yahoo.com - February 8 at 7:36 PM |
| Key Catalyst That Could Send Biotechs Soaring in 2017: Today's Reports on MYOS RENS Technology and Actinium Pharmaceuticals
finance.yahoo.com - February 6 at 9:40 AM |
| 2:55 pm MYOS RENS Tech. commences $2.125 common stock offering; to sell 500k shares at $4.25/share
us.rd.yahoo.com - February 4 at 5:31 AM |
 | MYOS RENS TECHNOLOGY INC
www.finanznachrichten.de - February 4 at 12:30 AM |
 | MYOS RENS Tech (MYOS) Reports $2.13M Registered Direct Offering of Common Stock
www.streetinsider.com - February 3 at 7:28 PM |
 | MYOS RENS Technology Inc. Announces $2,125,000 Registered Direct Offering
www.marketwatch.com - February 3 at 7:28 PM |
| Dr. Robert Hariri, stem cell pioneer and chairman of MYOS RENS Technology, states that 'healthy muscle is key to overall health and wellness'
finance.yahoo.com - January 30 at 9:31 AM |
| MYOS RENS TECHNOLOGY INC. Files SEC form 8-K, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Other
biz.yahoo.com - January 11 at 7:21 PM |
| MYOS RENS TECHNOLOGY INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders
biz.yahoo.com - December 22 at 7:02 PM |
| MYOS RENS TECHNOLOGY INC. Files SEC form 8-K, Entry into a Material Definitive Agreement
biz.yahoo.com - November 25 at 11:34 AM |
| 8:03 am MYOS RENS Tech. Announces Publication of Fortetropin Human Clinical Trial Manuscript demonstrating that it increased lean body mass, increased muscle thickness, and decreased markers of protein breakdown
finance.yahoo.com - September 29 at 11:25 AM |
| BRIEF-Myos Rens Technology appoints Joseph Mannello interim CEO
www.reuters.com - August 31 at 11:21 AM |
| MYOS RENS TECHNOLOGY INC. Files SEC form 8-K, Change in Directors or Principal Officers, Other Events
biz.yahoo.com - August 24 at 6:07 PM |
| MYOS RENS TECHNOLOGY INC. Files SEC form 8-K, Change in Directors or Principal Officers
biz.yahoo.com - June 29 at 4:17 PM |
| MYOS RENS TECHNOLOGY INC. Files SEC form 8-K, Changes in Registrant's Certifying Accountant
biz.yahoo.com - May 20 at 5:26 PM |
| MYOS RENS TECHNOLOGY INC. Files SEC form 10-Q, Quarterly Report
biz.yahoo.com - May 13 at 8:34 AM |
| MYOS Reports Positive Results From Fortetropin(R) Clinical Study
finance.yahoo.com - April 22 at 3:00 PM |
| MYOS RENS TECHNOLOGY INC. Files SEC form 10-K, Annual Report
biz.yahoo.com - March 30 at 5:53 PM |
| MYOS RENS TECHNOLOGY INC. Files SEC form 8-K, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Financ
biz.yahoo.com - March 22 at 4:33 PM |
| MYOS CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Unregistered Sale of Equity Securities, Cha
biz.yahoo.com - March 8 at 5:31 PM |
| MYOS Corporation Announces Election of New Directors and Appointment of Ren Ren as Global Chairman
finance.yahoo.com - March 8 at 4:17 PM |
| MYOS CORP Files SEC form 8-K, Change in Directors or Principal Officers, Other Events
biz.yahoo.com - February 4 at 5:21 PM |
MYOS RENS Technology (MYOS) Chart for Monday, September, 25, 2017
